# BAY43-9006 - Phase II in Advanced Breast Cancer

> **NCT00101400** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 54 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Cancer

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT00101400
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2006-01
- **Final completion:** 2008-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2013-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101400, "BAY43-9006 - Phase II in Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00101400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*